Concepedia

Nadia Salem

NS

3

Publications

63

Citations

3

H-Index

2006

Active since

Affiliations

Sigma-Tau Pharmaceuticals (United States)(Current)

Massachusetts General Hospital

Harvard University

Sigma Tau (Italy)

Nadia Salem is an author at Sigma-Tau Pharmaceuticals (United States) specializing in medicine, high-grade gliomas, and glioma.

Top concepts

Publications per year

2006–2012

3

Publications

3

A phase II trial of oral gimatecan for recurrent glioblastoma

Jethro Hu, Patrick Y. Wen, Lauren E. Abrey et al. · Journal of Neuro-Oncology · 2012 · 26 citations

, , +10

Phase I and Pharmacokinetic Study of Gimatecan Given Orally Once a Week for 3 of 4 Weeks in Patients with Advanced Solid Tumors

Andrew X. Zhu, Neal Ready, Jeffrey W. Clark et al. · Clinical Cancer Research · 2008 · 26 citations · Full text

Co-regulation of dopamine D1 receptor and uncoupling protein-2 expression in 3-nitropropionic acid-induced neurotoxicity: Neuroprotective role of l-carnitine

Zbigniew Binienda, Syed F. Ali, Ashraf Virmani et al. · Neuroscience Letters · 2006 · 11 citations

, , +6

Rows per page

1–3 of 3